Stocks and Investing
Stocks and Investing
Tue, April 2, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Roy Buchanan Upgraded (ANTX) to Buy and Held Target at $6 on, Apr 2nd, 2024
Roy Buchanan of JMP Securities, Upgraded "AN2 Therapeutics, Inc." (ANTX) to Buy and Held Target at $6 on, Apr 2nd, 2024.
Roy has made no other calls on ANTX in the last 4 months.
There are 3 other peers that have a rating on ANTX. Out of the 3 peers that are also analyzing ANTX, all agree with Roy's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Jeff Jones of "Oppenheimer" Reiterated at Hold on, Monday, April 1st, 2024
- Joseph Schwartz of "Leerink Partners" Downgraded from Buy to Hold and Decreased Target to $7 on, Tuesday, February 13th, 2024
- Liisa Bayko of "Evercore ISI Group" Downgraded from Buy to Hold and Decreased Target to $7 on, Monday, February 12th, 2024
Contributing Sources